0000950170-24-061275.txt : 20240517 0000950170-24-061275.hdr.sgml : 20240517 20240516185631 ACCESSION NUMBER: 0000950170-24-061275 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240515 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTOKINETICS INC CENTRAL INDEX KEY: 0001061983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943291317 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50633 FILM NUMBER: 24957279 BUSINESS ADDRESS: STREET 1: 350 OYSTER POINT BOULEVARD STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 624-3000 MAIL ADDRESS: STREET 1: 350 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 cytk-20240515.htm 8-K 8-K
0001061983false00010619832024-05-152024-05-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2024

 

 

Cytokinetics, Incorporated

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-50633

94-3291317

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

350 Oyster Point Boulevard

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 624-3000

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

CYTK

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”). Mr. Smith’s resignation was given in connection with his not being nominated for re-election at the Annual Meeting and was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

(e) At the Annual Meeting, the Company’s stockholders approved the amendment and restatement of the Company’s Amended and Restated 2015 Employee Stock Purchase Plan (the “ESPP”) to increase the number of shares of the Company’s common stock, par value $0.001 per share (“common stock”), authorized for issuance thereunder by 300,000 shares. The material features of the ESPP, as amended and restated, are described in the section entitled Proposal Two: Approval of the Amendment and Restatement of the Company’s Amended and Restated 2015 Employee Stock Purchase Plan to Increase the Number of Authorized Shares Reserved for Issuance Thereunder by 300,000 Shares of Common Stock on pages six through ten of the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2024 (the “2024 Proxy Statement”) in connection with the Annual meeting, which pages are incorporated herein by reference. The ESPP, as so amended and restated, is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for, against or withheld and the number of abstentions and broker non-votes with respect to each matter. Of the 104,576,087 shares of the Company’s common stock entitled to vote at the Annual Meeting, 96,181,650 shares of common stock, or 91.97%, of the total eligible votes to be cast, were represented at the Annual Meeting in person or by proxy, constituting a quorum. A more complete description of each matter is set forth in the 2024 Proxy Statement.

Proposal 1: Election of Two Class II Directors

The stockholders elected Robert I. Blum and Robert A. Harrington, M.D. as Class II Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows:

Name

For

Withheld

Broker

Robert I. Blum

87,317,169

2,214,926

6,649,555

Robert A. Harrington, M.D.

78,347,186

11,184,909

6,649,555

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock.

The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows:

For

Against

Abstain

Broker Non-Vote

88,586,473

481,098

464,524

6,649,555

Proposal 3: Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024

The stockholders ratified the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were as follows:

For

Against

Abstain

95,957,265

97,750

126,635

Proposal 4: Advisory Vote on Executive Compensation


The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the 2024 Proxy Statement. The votes were as follows:

For

Against

Abstain

Broker Non-Vote

85,814,395

2,927,007

790,693

6,649,555

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

10.1 Cytokinetics, Incorporated Amended and Restated 2015 Employee Stock Purchase Plan

104 Cover Page Interactive Data File (embedded in the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CYTOKINETICS, INCORPORATED

 

 

 

 

Date:

May 16, 2024

By:

/s/ John O. Faurescu

 

 

 

John O. Faurescu, Esq.
Associate General Counsel & Secretary

 


EX-10.1 2 cytk-ex10_1.htm EX-10.1 EX-10.1

CYTOKINETICS, INCORPORATED 2015 EMPLOYEE STOCK PURCHASE PLAN

ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 3, 2015 APPROVED BY THE STOCKHOLDERS: MAY 20, 2015

AMENDED AND RESTATED AND APPROVED BY THE STOCKHOLDERS: May 13, 2020

AMENDED AND RESTATED AND APPROVED BY THE STOCKHOLDERS: May 15, 2024

 

 

1.
PURPOSE AND EFFECTIVE DATE.
(a)
The purpose of this Amended and Restated 2015 Employee Stock Purchase Plan (the “Plan”) is to provide a means by which Eligible Employees of Cytokinetics, Incorporated and certain designated Related Corporations may be given an opportunity to purchase shares of the Company’s Stock. The Plan is intended to permit the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its related corporations. Capitalized terms have the meaning ascribed to them in Section 14.
(b)
The Plan became effective November 1, 2015 (the “Effective Date”). If approved by stockholders, the amendment to and restatement of the Plan will become effective on the date the stockholders vote to approve the Plan.

 

2.
ADMINISTRATION.
(a)
The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 2(c).
(b)
The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:
(i)
To determine how and when Purchase Rights to purchase shares of Stock will be granted and the provisions of each Offering of such Purchase Rights (which need not be identical).
(ii)
To designate from time to time which Related Corporations of the Company will be eligible to participate in the Plan.
(iii)
To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it will deem necessary or expedient to make the Plan fully effective.
(iv)
To settle all controversies regarding the Plan and Purchase Rights granted under it.
(v)
To suspend or terminate the Plan at any time as provided in Section 12.
(vi)
To amend the Plan at any time as provided in Section 12.
(vii)
Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan.
(viii)
To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.
(c)
The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.
(d)
All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

 

 

3.
SHARES OF STOCK SUBJECT TO THE PLAN.
(a)
Subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the shares of Stock that may be sold pursuant to Purchase Rights will not exceed in the aggregate 1,159,879 shares of Stock, which number consists of (i) 500,000 shares of Stock, plus (ii) 159,879 shares of Stock that were remaining in the reserve of the Company’s 2004 Employee Stock Purchase Plan upon its termination, plus 500,000 new shares of Stock.
(b)
If any Purchase Right granted under the Plan will terminate without having been exercised in full, the shares of Stock not purchased under such Purchase Right will again become available for issuance under the Plan.
(c)
The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Stock, including shares repurchased by the Company on the open market.

 

4.
GRANT OF PURCHASE RIGHTS; OFFERING.
(a)
The Board may from time to time grant or provide for the grant of Purchase Rights to purchase shares of Stock under the Plan to Eligible Employees in an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate, which will comply with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering will be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive.
(b)
If a Participant has more than one Purchase Right outstanding under the Plan, unless they otherwise indicate in agreements or notices delivered hereunder: (i) each agreement or notice delivered by that Participant will be deemed to apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.
(c)
The Board will have the discretion to structure an Offering so that if the Fair Market Value of the shares of Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of the shares of Stock on the Offering Date, then (i) that Offering will terminate immediately, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.

 

5.
ELIGIBILITY.
(a)
Purchase Rights may be granted only to Employees of the Company or, as the Board may designate as provided in Section 2(b), to Employees of a Related Corporation. Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee’s customary employment with the Company or the Related Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code.
(b)
The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right

 


 

will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:

(i)
the date on which such Purchase Right is granted will be the “Offering Date” of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right;
(ii)
the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and
(iii)
the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, such person will not receive any Purchase Right under that Offering.
(c)
No Employee will be eligible for the grant of any Purchase Rights under the Plan if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section 5(c), the rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.
(d)
As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights under the Plan only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time.
(e)
Officers of the Company and any designated Related Corporation who are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate.

 

6.
PURCHASE RIGHTS; PURCHASE PRICE.
(a)
On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee’s earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.
(b)
The Board will establish one or more Purchase Dates during an Offering as of which Purchase Rights granted pursuant to that Offering will be exercised and purchases of shares of Stock will be carried out in accordance with such Offering.
(c)
In connection with each Offering made under the Plan, the Board may specify a maximum number of shares of Stock that may be purchased by any Participant on any Purchase Date during such Offering. In connection with each Offering made under the Plan, the Board may specify a maximum aggregate number of shares of Stock that may be purchased by all Participants pursuant to such Offering. In addition, in connection with each Offering that contains more than one Purchase Date, the Board may specify a maximum aggregate number of shares of Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata allocation of the shares of Stock available will be made in as nearly a uniform manner as will be practicable and equitable.
(d)
The purchase price of shares of Stock acquired pursuant to Purchase Rights will be not less than the lesser of: (i) an amount equal to 85% of the Fair Market Value of the shares of Stock on the Offering Date; or (ii) an amount equal to 85% of the Fair Market Value of the shares of Stock on the applicable Purchase Date.

 

7.
PARTICIPATION; WITHDRAWAL; TERMINATION.
(a)
A Participant may elect to authorize payroll deductions pursuant to an Offering under the Plan by completing and delivering to the Company, within the time specified in the Offering, an enrollment form (in such form as the

 


 

Company may provide). Each such enrollment form will authorize an amount of Contributions expressed as a percentage of the submitting Participant’s earnings (as defined in each Offering) during the Offering (not to exceed the maximum percentage specified by the Board). Each Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a third party. To the extent provided in the Offering, a Participant may begin such Contributions after the beginning of the Offering. To the extent provided in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. To the extent specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to each Purchase Date of the Offering.

(b)
During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a notice of withdrawal in such form as the Company may provide. Such withdrawal may be elected at any time prior to the end of the Offering, except as provided otherwise in the Offering. Upon such withdrawal from the Offering by a Participant, the Company will distribute to such Participant all of his or her accumulated Contributions (reduced to the extent, if any, such Contributions have been used to acquire shares of Stock for the Participant) under the Offering, and such Participant’s Purchase Right in that Offering will thereupon terminate. A Participant’s withdrawal from an Offering will have no effect upon such Participant’s eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form in order to participate in subsequent Offerings.
(c)
Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately upon a Participant ceasing to be an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or other lack of eligibility. The Company will distribute to such terminated or otherwise ineligible Employee all of his or her accumulated Contributions (reduced to the extent, if any, such Contributions have been used to acquire shares of Stock for the terminated or otherwise ineligible Employee) under the Offering.
(d)
Purchase Rights will not be transferable by a Participant except by will, the laws of descent and distribution, or by a beneficiary designation as provided in Section 10. During a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant.
(e)
Unless otherwise specified in an Offering, the Company will have no obligation to pay interest on Contributions.

 

8.
EXERCISE OF PURCHASE RIGHTS.
(a)
On each Purchase Date during an Offering, each Participant’s accumulated Contributions will be applied to the purchase of shares of Stock up to the maximum number of shares of Stock permitted pursuant to the terms of the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued upon the exercise of Purchase Rights unless specifically provided for in the Offering.
(b)
If any amount of accumulated Contributions remains in a Participant’s account after the purchase of shares of Stock and such remaining amount is less than the amount required to purchase one share of Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant’s account for the purchase of shares of Stock under the next Offering under the Plan, unless such Participant withdraws from such next Offering, as provided in Section 7(b), or is not eligible to participate in such Offering, as provided in Section 5, in which case such amount will be distributed to such Participant after the final Purchase Date, without interest. If the amount of Contributions remaining in a Participant’s account after the purchase of shares of Stock is at least equal to the amount required to purchase one whole share of Stock on the final Purchase Date of the Offering, then such remaining amount will be distributed in full to such Participant at the end of the Offering without interest.
(c)
No Purchase Rights may be exercised to any extent unless the shares of Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan. If on a Purchase Date during any Offering hereunder the shares of Stock are not so registered or the Plan is not in such compliance, no Purchase Rights or any Offering will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Stock are subject to such an effective registration statement and the Plan is in such compliance, except that the Purchase Date will not be delayed more than 12 months and the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date under any Offering hereunder, as delayed to the maximum extent permissible, the shares of Stock are not registered and the Plan is not in such compliance, no Purchase Rights or any Offering will be exercised and all Contributions accumulated during the

 


 

Offering (reduced to the extent, if any, such Contributions have been used to acquire shares of Stock) will be distributed to the Participants without interest.

 

9.
COVENANTS OF THE COMPANY.

The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan such authority as may be required to issue and sell shares of Stock upon exercise of the Purchase Rights. If, after commercially reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Stock upon exercise of such Purchase Rights unless and until such authority is obtained.

 

10.
DESIGNATION OF BENEFICIARY.
(a)
A Participant may file a written designation of a beneficiary who is to receive any shares of Stock and/or cash, if any, from the Participant’s account under the Plan in the event of such Participant’s death subsequent to the end of an Offering but prior to delivery to the Participant of such shares of Stock or cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant’s account under the Plan in the event of such Participant’s death during an Offering. Any such designation will be on a form provided by or otherwise acceptable to the Company.
(b)
The Participant may change such designation of beneficiary at any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant’s death, the Company will deliver such shares of Stock and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Stock and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

 

11.
ADJUSTMENTS UPON CHANGES IN STOCK; CORPORATE TRANSACTIONS.
(a)
In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the class(es) and number of securities imposed by purchase limits under each ongoing Offering. The Board will make such adjustments, and its determination will be final, binding and conclusive.
(b)
In the event of a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue Purchase Rights outstanding under the Plan or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for those outstanding under the Plan, or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute similar rights for Purchase Rights outstanding under the Plan, then the Participants’ accumulated Contributions will be used to purchase shares of Stock within ten (10) business days prior to the Corporate Transaction under any ongoing Offerings, and the Participants’ Purchase Rights under the ongoing Offerings will terminate immediately after such purchase.

 

12.
AMENDMENT, TERMINATION OR SUSPENSION OF THE PLAN.
(a)
The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements, including any amendment that either (i) materially increases the number of shares of Stock available for issuance under the Plan, (ii) materially expands the class of individuals eligible to become Participants and receive Purchase Rights under the Plan, (iii) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Stock may be purchased under the Plan, (iv) materially extends the term of the Plan, or (v) expands the types of awards available for issuance under the Plan, but in each of (i) through (v) above only to the extent stockholder approval is required by applicable law or listing requirements.
(b)
The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated.

 


 

(c)
Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the Effective Date, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment.

 


 

 

13.
MISCELLANEOUS PROVISIONS.
(a)
Proceeds from the sale of shares of Stock pursuant to Purchase Rights will constitute general funds of the Company.
(b)
A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Stock subject to Purchase Rights unless and until the Participant’s shares of Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent).
(c)
The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant’s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant.
(d)
The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state’s conflicts of laws rules.

 

14.
DEFINITIONS.

The following definitions will apply to the capitalized terms used in the Plan:

(a)
“Board” means the Board of Directors of the Company.
(b)
“Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Stock subject to the Plan or subject to any Purchase Right after the Effective Date without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar transaction). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.
(c)
“Code” means the Internal Revenue Code of 1986, as amended.
(d)
“Committee” means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c).
(e)
“Company” means Cytokinetics, Incorporated, a Delaware corporation.
(f)
“Contributions” means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account, if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions.
(g)
“Corporate Transaction” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:
(i)
the sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;
(ii)
the sale or other disposition of at least 90% of the outstanding securities of the Company;
(iii)
the merger, consolidation or similar transaction following which the Company is not the surviving corporation; or
(iv)
the merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.
(h)
“Director” means a member of the Board.
(i)
“Eligible Employee” means an Employee who meets the requirements set forth in the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan.
(j)
“Employee” means any person who is employed for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation.
(k)
“Employee Stock Purchase Plan” means a plan that grants Purchase Rights intended to be options issued under an “employee stock purchase plan,” as defined in Section 423(b) of the Code.

 


 

(l)
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
(m)
“Fair Market Value” means, as of any date, the value of the Stock determined as follows:
(i)
If the Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Stock) on the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Stock on the date of determination, then the Fair Market Value will be the closing selling price (or closing bid if no sales were reported) on the last preceding date for which such quotation exists.
(ii)
In the absence of such markets for the Stock, the Fair Market Value will be determined by the Board in good faith.
(n)
“Offering” means the grant of Purchase Rights to purchase shares of Stock under the Plan to Eligible Employees.
(o)
“Offering Date” means a date selected by the Board for an Offering to commence.
(p)
“Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.
(q)
“Participant” means an Eligible Employee who holds an outstanding Purchase Right granted pursuant to the Plan.
(r)
“Plan” means this Cytokinetics, Incorporated 2015 Employee Stock Purchase Plan.
(s)
“Purchase Date” means one or more dates during an Offering established by the Board on which Purchase Rights will be exercised and as of which purchases of shares of Stock will be carried out in accordance with such Offering.
(t)
“Purchase Period” means a period of time specified within an Offering beginning on the Offering Date or on the next Trading Day following a Purchase Date within an Offering and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods.
(u)
“Purchase Right” means an option to purchase shares of Stock granted pursuant to the Plan.
(v)
“Related Corporation” means any “parent corporation” or “subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.
(w)
“Securities Act” means the Securities Act of 1933, as amended.
(x)
“Stock” means the Common Stock of the Company.
(y)
“Trading Day” means any day on which the exchange(s) or market(s) on which shares of Stock are listed, including the NASDAQ Global Select Market, the NASDAQ Global Market, or the NASDAQ Capital Market, is open for trading.

 


 

* * * *

 


EX-101.SCH 3 cytk-20240515.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
May 15, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 15, 2024
Entity Registrant Name Cytokinetics, Incorporated
Entity Central Index Key 0001061983
Entity Emerging Growth Company false
Entity File Number 000-50633
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3291317
Entity Address, Address Line One 350 Oyster Point Boulevard
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 624-3000
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol CYTK
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports cytk-20240515.htm cytk-20240515.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cytk-20240515.htm": { "nsprefix": "cytk", "nsuri": "http://cytokinetics.com/20240515", "dts": { "inline": { "local": [ "cytk-20240515.htm" ] }, "schema": { "local": [ "cytk-20240515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_b343f2d9-14c0-41d1-b11f-2c1f52db30ca", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cytk-20240515.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b343f2d9-14c0-41d1-b11f-2c1f52db30ca", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "cytk-20240515.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://cytokinetics.com/20240515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-061275-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-061275-xbrl.zip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end XML 15 cytk-20240515_htm.xml IDEA: XBRL DOCUMENT 0001061983 2024-05-15 2024-05-15 0001061983 false 8-K 2024-05-15 Cytokinetics, Incorporated DE 000-50633 94-3291317 350 Oyster Point Boulevard South San Francisco CA 94080 (650) 624-3000 N/A false false false false Common Stock, $0.001 par value CYTK NASDAQ false